In The News

Ropes & Gray Advises Akebia Therapeutics on Initial Public Offering

Practices: Capital Markets, Mergers & Acquisitions, Life Sciences, Life Sciences Mergers & Acquisitions, Securities & Public Companies

Ropes & Gray recently advised Akebia Therapeutics Inc. on its initial public offering of 6.7 million shares of its common stock at a price of $17 per share. Akebia is a Cambridge, Mass.-based biopharmaceutical company developing novel therapeutics aimed at patients with kidney disease. The IPO was announced Feb. 18 and closed March 25, with the net proceeds of the offering totaling $106.9 million.

Christopher Comeau led the Ropes & Gray team representing Akebia. 

Cookie Settings